Educational use only. Check doses against the product monograph and local protocols.

osteoporosis agents

in review 4 min read Updated 2026-11-19
osteoporosis agents

Antiresorptives (bisphosphonates, denosumab, raloxifene) suppress osteoclasts; anabolics (teriparatide, romosozumab) build bone and must be followed by an antiresorptive. Oral bisphosphonates are first-line (avoid if CrCl <30–35). Denosumab works at any eGFR (watch severe hypocalcaemia in CKD) but causes rebound vertebral fractures if delayed or stopped without a bisphosphonate bridge.

atypical femoral fracture (AFF) and denosumab rebound
  • Thigh or groin pain on antiresorptives: obtain bilateral femur X-rays (lateral cortical thickening/beaking, transverse subtrochanteric line). If AFF confirmed → stop bisphosphonate, consult orthopaedics (IM nail), image contralateral femur, and consider teriparatide (not denosumab).
  • Denosumab: never delay q6-month injections >1 month and never stop without transitioning to a bisphosphonate.

mechanism

  • Bisphosphonates: bind hydroxyapatite and induce osteoclast apoptosis; persist in bone matrix for years (allowing drug holidays).
  • Denosumab: human monoclonal antibody against RANKL → blocks osteoclast maturation/survival; fully reversible upon clearance.
  • Teriparatide: recombinant PTH(1–34) given intermittently daily → net osteoblastic bone formation.
  • Romosozumab: monoclonal antibody against sclerostin → dual effect (↑ bone formation + ↓ resorption).
  • Raloxifene: SERM with oestrogen-agonist effect on bone and antagonist effect on breast/endometrium.

comparison and dosing

Ensure adequate calcium and vitamin D; correct hypocalcaemia before any antiresorptive and replete severe vitamin D deficiency before parenteral potent antiresorptives (denosumab or zoledronic acid, which carry high hypocalcaemia risk; oral bisphosphonates can be started alongside vitamin D repletion when serum calcium is normal).

agentosteoporosis doserenal limitmajor contraindicationskey clinical notes
alendronate70 mg PO weekly (Paget: 40 mg/day × 6 mo)CrCl <30–35 mL/minoesophageal stricture/achalasia, inability to stay upright 30 min, hypocalcaemiatake fasting with plain water; upright & nothing by mouth 30–60 min; first-line
risedronate35 mg PO weekly or 150 mg monthly (Paget: 30 mg/day × 2 mo)CrCl <30–35 mL/minsame as alendronatedelayed-release formulation can be taken immediately after breakfast
zoledronic acid5 mg IV annually (HCM: 4 mg IV; Paget: single 5 mg IV)CrCl <35 mL/minhypocalcaemia, CrCl <35flu-like acute-phase reaction (acetaminophen helps); consider dosing q18–24 mo after 3 y
denosumab60 mg SC q6 months (HCM: 120 mg SC)no eGFR cut-off (extreme hypoCa risk in CKD 4–5/dialysis)hypocalcaemiareserve for bisphosphonate intolerance/contraindication; never stop without bisphosphonate bridge
teriparatide20 µg SC daily × max 24 monthsCrCl <30 mL/minPaget disease, skeletal radiation, bone malignancy/mets, hypercalcaemia, unexplained ↑ ALPanabolic for very high risk or post-AFF; follow with antiresorptive
romosozumab210 mg SC monthly × 12 monthscaution in severe CKD (hypoCa)prior MI or stroke (CV boxed warning), hypocalcaemiapotent dual-action anabolic; follow with antiresorptive
raloxifene60 mg PO dailynoneVTE, CVD/stroke, premenopausalvertebral fracture reduction only (no hip benefit); worsens hot flashes; ↓ ER+ breast cancer

key points

  • Drug holiday (bisphosphonates only): after 3–6 years of bisphosphonates, pausing therapy reduces AFF risk (risk drops sharply within 2 years of stopping) while residual skeletal bisphosphonate maintains partial protection. Never take a drug holiday from denosumab, raloxifene, or anabolics.
  • Osteonecrosis of the jaw (ONJ): exposed jawbone persisting >8 weeks; rare at osteoporosis doses (far higher at monthly oncology IV dosing) — encourage routine dental hygiene; do not delay urgent fracture prevention for routine dental cleanings.
  • Ontario: Oral bisphosphonates are general benefit. ODB Limited Use covers zoledronic acid (LU 436 postmenopausal OP, LU 523 male OP, LU 319 Paget), denosumab biosimilars (LU 687 postmenopausal, LU 688 male — high risk + failed/intolerant to oral bisphosphonate), and teriparatide (LU 635 / 676 — severe osteoporosis criteria).

adverse effects

  • Oral bisphosphonates: oesophagitis/dyspepsia, musculoskeletal pain, rare AFF & ONJ.
  • IV zoledronic acid: acute-phase fever/myalgias (24–72 h), nephrotoxicity if CrCl <35, hypocalcaemia, rare AFF & ONJ.
  • Denosumab: severe prolonged hypocalcaemia (especially CKD 4–5 / vitamin D deficiency), cellulitis/dermatitis, rebound vertebral fractures on stopping, rare AFF & ONJ.
  • Teriparatide: orthostatic hypotension, hypercalcaemia/hypercalciuria, nausea, leg cramps.
  • Romosozumab: MI / stroke / CV death, hypocalcaemia, injection-site reactions, rare AFF & ONJ.
  • Raloxifene: VTE, fatal stroke signal, hot flashes, leg cramps.

Prepared 2026-11-19. Not yet verified — check every number against the sources.

Key references

+1 more source

Suggest a correction osteoporosis agents